HDAC9 and cancer: HDAC inhibitors (HDACi) are potent inducers of EBV reactivation, which is critical for expression of lytic proteins, thereby providing novel targets for therapy as well as mediating the enhanced killing of cancer cells when used alone or with additional anti-cancer agents in EBV-associated malignancies51,52.